Leerink Partnrs Has Bullish Outlook for CRBU FY2025 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities researchers at Leerink Partnrs raised their FY2025 earnings per share estimates for Caribou Biosciences in a note issued to investors on Wednesday, November 12th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($1.38) per share for the year, up from their previous forecast of ($1.57). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Leerink Partnrs also issued estimates for Caribou Biosciences’ Q4 2025 earnings at ($0.30) EPS, FY2026 earnings at ($1.65) EPS, FY2027 earnings at ($1.73) EPS, FY2028 earnings at ($2.05) EPS and FY2029 earnings at ($0.72) EPS.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. Caribou Biosciences had a negative return on equity of 69.85% and a negative net margin of 1,690.45%.The firm had revenue of $2.20 million during the quarter, compared to analysts’ expectations of $1.94 million.

Several other equities analysts also recently issued reports on CRBU. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Wednesday, October 8th. HC Wainwright boosted their price target on Caribou Biosciences from $3.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Citigroup increased their price target on Caribou Biosciences from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, November 3rd. Truist Financial set a $7.00 price objective on Caribou Biosciences in a report on Tuesday, November 4th. Finally, Wall Street Zen upgraded Caribou Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 24th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Caribou Biosciences Price Performance

Caribou Biosciences stock opened at $1.87 on Monday. The stock has a market capitalization of $174.79 million, a P/E ratio of -1.10 and a beta of 2.59. Caribou Biosciences has a 12-month low of $0.66 and a 12-month high of $3.54. The firm’s 50-day moving average is $2.24 and its two-hundred day moving average is $1.77.

Institutional Trading of Caribou Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in CRBU. Next Capital Management LLC acquired a new position in Caribou Biosciences in the second quarter valued at $25,000. Creative Planning acquired a new stake in Caribou Biosciences during the second quarter worth about $25,000. R Squared Ltd purchased a new position in shares of Caribou Biosciences in the 3rd quarter worth about $29,000. Hudson Bay Capital Management LP acquired a new position in shares of Caribou Biosciences in the 2nd quarter valued at about $30,000. Finally, Savant Capital LLC acquired a new position in shares of Caribou Biosciences in the 2nd quarter valued at about $36,000. 77.51% of the stock is currently owned by institutional investors and hedge funds.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.